What is Synthex?
Synthex operates at the vanguard of the biotechnology sector, specializing in target-centric, cell-based functional selection. By leveraging its proprietary ToR platform, the company addresses the critical challenge of accessing previously undruggable proteins. This innovative methodology allows for the engineering of cells capable of identifying rare, selective compounds that modulate complex protein targets. By exploring novel mechanisms of action, Synthex provides essential value to the pharmaceutical and biotechnology industries, facilitating the development of next-generation therapeutics for complex diseases. The company's strategic focus on high-barrier-to-entry protein targets positions it as a critical partner in the modern drug discovery ecosystem.
How much funding has Synthex raised?
Synthex has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Synthex
PPP
Public-Private Partnership
What's next for Synthex?
Following this major strategic investment, Synthex is well-positioned to scale its operational capacity and accelerate its research and development pipeline. The capital will likely be deployed to expand the utility of the ToR platform, potentially broadening the scope of therapeutic candidates currently in the discovery phase. As the company transitions through this late-stage growth phase, the focus will shift toward establishing high-value partnerships with global pharmaceutical entities and advancing lead compounds toward clinical validation. The firm's ability to navigate the complexities of protein modulation will be the primary driver of its long-term valuation and market influence.
See full Synthex company page
